S.C. Wei, C.R. Duffy, J.P. Allison, Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069–1086 (2018). https://doi.org/10.1158/2159-8290.CD-18-0367

Article  PubMed  Google Scholar 

J.J. Havel, D. Chowell, T.A. Chan, The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer. 19, 133–150 (2019). https://doi.org/10.1038/s41568-019-0116-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

P. Sharma, S. Goswami, D. Raychaudhuri, B.A. Siddiqui, P. Singh, A. Nagarajan, J. Liu, S.K. Subudhi, C. Poon, K.L. Gant et al., Immune checkpoint therapy—current perspectives and future directions. Cell. 186, 1652–1669 (2023). https://doi.org/10.1016/j.cell.2023.03.006

Article  CAS  PubMed  Google Scholar 

D. Karaviti, E.R. Kani, E. Karaviti, E. Gerontiti, O. Michalopoulou, K. Stefanaki, P. Kazakou, V. Vasileiou, T. Psaltopoulou, S.A. Paschou, Thyroid disorders induced by immune checkpoint inhibitors. Endocrine. 85, 67–79 (2024). https://doi.org/10.1007/s12020-024-03718-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

T. Yan, L. Yu, J. Zhang, Y. Chen, Y. Fu, J. Tang, D. Liao, Achilles’ heel of currently approved immune checkpoint inhibitors: immune related adverse events. Front. Immunol. 15, 1292122 (2024). https://doi.org/10.3389/fimmu.2024.1292122

Article  CAS  PubMed  PubMed Central  Google Scholar 

I. Yamauchi, D. Yabe, Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors. Eur. Thyroid J. 14 (2025). https://doi.org/10.1530/ETJ-24-0328

X. Li, Z. Song, Y. Chen, J. Wu, D. Jiang, Z. Zhang, Z. Wang, R. Zhao, Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal. Cancer Immunol. Immunother. 74, 2 (2024). https://doi.org/10.1007/s00262-024-03816-0

Article  PubMed  PubMed Central  Google Scholar 

M. Stelmachowska-Banaś, I. Czajka-Oraniec, Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocr. Connect. 9, R207–R228 (2020). https://doi.org/10.1530/EC-20-0342

Article  PubMed  PubMed Central  Google Scholar 

S. Iwama, T. Kobayashi, Y. Yasuda, T. Okuji, M. Ito, M. Ando, X. Zhou, A. Yamagami, T. Onoue, Y. Kawaguchi et al., Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline. J. Clin. Endocrinol. Metab. 107, e1620–e1630 (2022). https://doi.org/10.1210/clinem/dgab829

Article  PubMed  Google Scholar 

L. Zhan, H.F. Feng, H.Q. Liu, L. Guo, C. Chen, X. Yao, S. Sun, Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management. Front. Endocrinol. 12, 649863 (2021). https://doi.org/10.3389/fendo.2021.649863

Article  Google Scholar 

J.J. Wright, D.B. Johnson, Approach to the patient with immune checkpoint inhibitor–associated endocrine dysfunction. J. Clin. Endocrinol. Metab. 108, 1514–1525 (2023). https://doi.org/10.1210/clinem/dgac689

Article  PubMed  PubMed Central  Google Scholar 

El R. Sabbagh, N.S. Azar, A.A. Eid, S.T. Azar, Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review. Int. J. Gen. Med. Volume. 1003–1009 (2020). https://doi.org/10.2147/IJGM.S261433

C.A. Muir, C.C. Wood, R.J. Clifton-Bligh, G.V. Long, R.A. Scolyer, M.S. Carlino, A.M. Menzies, V.H.M. Tsang, Association of antithyroid antibodies in checkpoint inhibitor–associated thyroid immune–related adverse events. J. Clin. Endocrinol. Metab. 107, e1843–e1849 (2022). https://doi.org/10.1210/clinem/dgac059

Article  PubMed  Google Scholar 

N. Marrano, M. Caporusso, C. Ganini, A. Borraccino, A. Cignarelli, S. Perrini, L. Laviola, C. Porta, F. Giorgino, A. Natalicchio, Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors. J. Endocrinol. Invest. 49, 399–412 (2026). https://doi.org/10.1007/s40618-025-02732-z

Article  CAS  PubMed  Google Scholar 

M. Gilon, D. Boulet, V. Bours, G. Jerusalem, C. Josse, C. Gennigens, Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies. J. Exp. Clin. Cancer Res. 45 (2026). https://doi.org/10.1186/s13046-026-03688-5

X. Zhou, S. Iwama, T. Kobayashi, M. Ando, H. Arima, Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline. J. Clin. Endocrinol. Metab. 108, e1056–e1062 (2023). https://doi.org/10.1210/clinem/dgad231

Article  CAS  PubMed  Google Scholar 

L. Jing, Q. Zhang, Intrathyroidal feedforward and feedback network regulating thyroid hormone synthesis and secretion. Front. Endocrinol. 13, 992883 (2022). https://doi.org/10.3389/fendo.2022.992883

Article  Google Scholar 

I.C. Arnold, A. Munitz, Spatial adaptation of eosinophils and their emerging roles in homeostasis, infection and disease. Nat. Rev. Immunol. 24, 858–877 (2024). https://doi.org/10.1038/s41577-024-01048-y

Article  CAS  PubMed  Google Scholar 

Y. Yasuda, S. Iwama, D. Sugiyama, T. Okuji, T. Kobayashi, M. Ito, N. Okada, A. Enomoto, S. Ito, Y. Yan et al., CD4+ T cells are essential for the development of destructive thyroiditis induced by anti–PD-1 antibody in thyroglobulin-immunized mice. Sci. Transl Med. 13, eabb7495 (2021). https://doi.org/10.1126/scitranslmed.abb7495

Article  CAS  PubMed  Google Scholar 

P.M. Leru, Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm. Clin. Transl Allergy. 9, 36 (2019). https://doi.org/10.1186/s13601-019-0277-4

Article  PubMed  PubMed Central  Google Scholar 

S. Takayasu, S. Mizushiri, Y. Watanuki, S. Yamagata, M. Usutani, Y. Nakada, Y. Asari, S. Murasawa, K. Kageyama, M. Daimon, Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study. Sci. Rep. 12, 1294 (2022). https://doi.org/10.1038/s41598-022-05400-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

K. Manaka, J. Sato, M. Takeuchi, K. Watanabe, H. Kage, T. Kawai, Y. Sato, T. Miyagawa, D. Yamada, H. Kume et al., Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency. Sci. Rep. 11, 11617 (2021). https://doi.org/10.1038/s41598-021-91032-6

Article  CAS  PubMed  PubMed Central  Google Scholar